:חפש לפי שם
המידע באתר אינו מהווה בשום אופן תחליף להתייעצות עם רופא או רוקח
אין להסתמך על המידע המופיע באתר זה כמקור מידע יחיד
שימוש או צפייה בנתונים באתר זה מעידים על הסכמתך לתנאי השימוש
לחץ/י כאן לצפיה בתנאי השימוש
  אתר ארגון הרוקחות צור קשר שאלות מידע תרופתי אודות המאגר  

:תרופות אחרות בעלות אותם מרכיבים

KEYTRUDA 100 MG/4 ML
 
KEYTRUDA 50 MG קיטרודה 50 מ"ג  
        תרופת מרשם
    עלון לרופא  


כן, יש ללחוץ כאן לפירוט בסל הבריאות?:
- Melanoma:Keytruda (pembrolizumab) is indicated for the treatment of patients with unresectable or metastatic melanoma . - Non-Small Cell Lung Cancer:Keytruda is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 [Tumor Proportion Score (TPS) ≥50%)] as determined by a validated test. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on or after platinum-containing chemotherapy and an approved therapy for these aberrations prior to receiving Keytruda.Keytruda is indicated for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors express PD-L1 as determined by a validated test, with disease progression on or after platinum containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on approved therapy for these aberrations prior to receiving Keytruda.- Head and Neck Cancer :Keytruda is indicated for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or after platinum-containing chemotherapy.- Classical Hodgkin LymphomaKeytruda is indicated for the treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL), or who have relapsed after 3 or more prior lines of therapy .- Urothelial CarcinomaKeytruda is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.- Microsatellite Instability-High Cancer:Keytruda is indicated for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient? solid tumors that have progressed following prior systemic treatment and who have no satisfactory alternative treatment options, or? colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan Limitation of Use: The safety and effectiveness of Keytruda in pediatric patients with MSI-H central nervous system cancers have not been established- Gastric Cancer:Keytruda is indicated for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by a validated test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu-targeted therapy התוויה מאושרת:
POWDER FOR SOLUTION FOR INFUSION דרך מתן:
MERCK SHARP & DOHME ISRAEL LTD בעל רישום:
153-43-34324-00 מספר רישום:
רכיב פעיל כמות
PEMBROLIZUMAB 50 MG/VIAL
ATC description
MONOCLONAL ANTIBODIES
ATC-ניתן ללחוץ על קבוצת ה
INFO ON THE WEB מידע ברשת




חזור לחיפוש תרופות | אתר ארגון הרוקחות | צור קשר | שאלות נפוצות | אודות המאגר